Wael Hozaeel

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · The Lancet · 2019 · 2.4K citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +9

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 713 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +12

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)

S-E. Al-Batran, Wael Hozaeel, Felix Tauchert et al. · Annals of Oncology · 2015 · 62 citations · Full text

Quality Of Life, Oncology, Health-related Quality +7

Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.

Salah‐Eddin Al‐Batran, Alexander Reichart, Ulli Simone Bankstahl et al. · Journal of Clinical Oncology · 2021 · 36 citations

Surgical Oncology, Cancer Management, Pathology +19

IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial.

Uğur Şahin, Salah‐Eddin Al‐Batran, Wael Hozaeel et al. · Journal of Clinical Oncology · 2015 · 20 citations

Esophageal Cancer, Cancer Management, Immunology +22